| Pharmaceutical Information |
| Drug Name |
Porfimer sodium |
| Drug ID |
BADD_D01803 |
| Description |
The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States. |
| Indications and Usage |
Indicated in the treatment of esophageal cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XD01 |
| DrugBank ID |
DB00707
|
| KEGG ID |
D03327
|
| MeSH ID |
D017323
|
| PubChem ID |
135577896
|
| TTD Drug ID |
D02JDL
|
| NDC Product Code |
76128-155 |
| UNII |
Y3834SIK5F
|
| Synonyms |
Dihematoporphyrin Ether | Ether, Dihematoporphyrin | Dihematoporphyrin Ester | Porfimer | DHP Ether | Porfimer Sodium | Photofrin | Photofrin II |
|
| Chemical Information |
| Molecular Formula |
C68H74N8O11 |
| CAS Registry Number |
87806-31-3 |
| SMILES |
CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4C)C(C)OC(C)C6=C(C7=CC
8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C
)C(=C3CCC(=O)O)C)CCC(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
